Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 4
Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies
Panelists discuss how first- and second-line treatment options for HR+ advanced/metastatic breast cancer, particularly the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy, are influenced by clinical factors such as bone metastasis, visceral crisis, and molecular phenotype, while also reviewing the latest clinical trial data, real-world outcomes, and comparative efficacy of ribociclib, abemaciclib, and palbociclib.
Video content above is prompted by the following:
- What are the available first- or second-line treatment options for HR+ advanced/metastatic breast cancer? (CDK4/6i +/- ET, etc.)
- What is the rationale for using CDK4/6i and ET in the front line?
- What are the main considerations when selecting frontline therapy? (bone metastases, visceral crisis, menopause status, recurrence score, nodal status, molecular phenotype, etc)
- Primary results from the Phase II RIGHT Choice trial
- SABCS PS2-06: Lu et al., RIGHT Choice trial subanalysis by intrinsic subtype & gene & signature expression.
- Real-world treatment outcomes (CDK4/6 inhibitors + endocrine therapy)
- OS analysis of first-line CDK4/6 inhibitors in real-world cohort
- What are the CDK4/6i options? Please briefly mention the main clinical trials and recent data:
- Ribociclib - MONALEESA-2, MONALEESA-7, MONALEESA-3
- ctDNA associated with PFS and OS in MONALEESA-3 (ML-3).
- Abemaciclib - MONARCH-3
- Final OS Analysis of Monarch 2
- Palbociclib - PALOMA-2, PARSIFAL
- Nationwide real-world practice pattern and clinical data of palbociclib
- SABCS 2024 LB1-03: Loibl et al, Primary results of the randomised phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy - PADMA study.
- Lerociclib: LEONARDA-1
- LEONARDA-2: Lerociclib plus letrozole
- How do the data for the 3 CDK4/6i compare?
Related Content:
